Aarti Industries FY26: Higher Volumes, Better Revenue, and a Clearer FY27 Execution Map

Aarti Industries closed FY26 with a set of numbers that look stronger on the surface, but still carry the familiar specialty chemicals tension between volume recovery and margin pressure. Consolidated gross income rose to 9018 crore versus 8046 crore in FY25, while EBITDA increased to 1172 crore from 1016 crore. Profit after tax improved to 419 crore from 331 crore.

The year also came with unusual volatility in the operating environment. The presentation describes FY26 as a roller coaster year, shaped by trade actions and geopolitics, including US tariff related developments, competitive moves out of China, and a late-year spike in raw material prices linked to the West Asia conflict. In that context, the revenue lift and the return of stronger utilization across several value chains matter because they suggest demand is healing in parts of the end market mix, even as profitability stays under pressure.

The company is positioning FY27 as an execution year. Multiple projects are expected to commission in FY27, including Zone IV, and joint ventures under execution. Aarti Industries is also leaning on two kinds of levers that investors typically want to see in a down cycle: hard cost improvement programs and long-duration customer contracts that can help utilization and cash flow stability.

A diversified portfolio that still depends on cycle turns

Aarti Industries is an integrated specialty chemicals and intermediates player with key value chains in Nitro Chloro Benzenes, Di-Chlorobenzenes, Phenyledeniamines, Nitro Toluene value chain, and Sulphuric Acid and downstream. It operates 16 manufacturing plants, including 11 zero liquid discharge plants, and runs 5 co-generation power plants. The scale is matched by breadth: the company lists over 100 products, over 1100 third and global customers, exports to 60 countries, and employs over 5800 people.

The end-use mix shows why the operating story can swing quickly. In FY26, energy was the largest application bucket at 43 percent of revenue, up from 36 percent in FY25. Agrochemicals and fertilizers stayed at 18 percent, while polymers and additives were 14 percent. Dyes, pigments and printing inks were 11 percent, and pharma was 10 percent.

Within that mix, the company notes that agrochemical volumes are showing steady growth but margins remain under pressure. Energy volumes were higher on favorable blending economics and expanded capacities, with volume increases across the US and EMEA regions. Polymers and additives saw good demand and volumes, especially for China EV markets, while US volume recovery is underway. Pharma volumes were steady, with expectations of improvement.

Geographically, the company highlights diversification across regions. North America contributes 25 percent of revenue and Europe 11 percent, with the rest spread across the Middle East and multiple Asia buckets. The implication is that the company is not tied to a single demand center, but it is exposed to global policy shocks and freight economics, especially when export volumes ramp.

Financial summary

The management commentary attached to these numbers points to three important undercurrents.

First, FY26 volume growth exceeded 30 percent, with substantial growth in export volumes. But competitive intensity kept EBITDA growth muted relative to the volume rebound. Second, the company saw exceptional items linked to tax appeal outcomes and one-off expenses, including exceptional income of 29 crore and exceptional expense of 22 crore, along with a new labour code impact and a write-off. Third, the West Asia conflict near the end of FY26 drove raw material prices up, which pushed working capital and debt levels higher.

Utilization recovery and the hard reality of product-level pressures

The most concrete sign of operating recovery is visible in capacity and utilization for major product groups. In FY26, several value chains moved closer to the kind of operating levels that can support better fixed-cost absorption.

NCB volumes rose to 92.7 KTPA from 85.3 KTPA in FY25, a 9 percent year-on-year increase, with utilization at 86 percent. DCB volumes increased to 96.5 KTPA from 88.6 KTPA, also 9 percent higher, with utilization at 80 percent. Hydrogenation volumes reached 50.8 KTPA, up 14 percent, at 85 percent utilization. NT volumes reached 37.0 KTPA, up 26 percent, at 82 percent utilization. Ethylation volumes rose to 20.5 KTPA, up 41 percent, at 82 percent utilization.

The standout is MMA and fuel additives. Volumes in this group jumped to 237.6 KTPA in FY26 from 123 KTPA in FY25, a 93 percent year-on-year increase, with utilization at 86 percent. The company notes that fuel additive capacity was at full utilization toward the end of the year and was expanded further to 360 kT in Q1FY27.

Not every pocket is improving. PDA volumes rose sharply in FY26 to 6.6 KTPA from 3.9 KTPA in FY25, a 69 percent increase, but utilization is still only 55 percent. Management attributes the pressure to US tariffs and competition from China, and it expects the category to remain under pressure.

This product-level picture matters because it shows what kind of recovery Aarti Industries is getting. It is not a single end-market boom. It is a patchwork improvement across energy-linked products, select agro and polymer demand, and broader utilization improvement in core chains like NCB and DCB. At the same time, tariff shocks and China competition can still trap some products below optimal utilization.

Contracts, partnerships, and sustainability: building the FY27 bridge

Aarti Industries is trying to reduce the risk of relying purely on spot demand by deepening customer relationships and moving upstream where it improves resilience. In March 2026, the company entered a material amendment to an existing exclusive long-term supply contract. Under the expanded scope, it will execute a backward integration project to manufacture a significant part of feedstock that is currently supplied by the customer. Management frames the benefit as opex and freight optimization and improved supply chain resilience, and it expects the amendment to positively enhance EBITDA over the remaining period of 15 years under the original agreement. The investment planned is about 200 to 250 crore over the next two years.

In parallel, the company signed a 150 million US dollar multi-year supply agreement with a top global agrochemicals innovator till March 2030. The product is part of an existing Aarti Industries value chain, and the company states it has adequate capacities. That matters because it suggests utilization-led growth without significant incremental capex, with volume growth progressively visible from FY27.

Partnerships and joint ventures are a second pillar of the FY27 setup. The Augene JV and Re Aarti JV are under execution and expected to commission in FY27. The company has also signed two additional long-term contracts in Q4 in line with its long-term growth strategy.

The JV pipeline includes a DCA downstream JV with Superform, expected to commission in H1FY27. Management notes tailwinds in one of the end applications, which may support quicker utilization. Another project is chemical recycling of plastics, where equipment deliveries are underway, on-ground execution is in full swing, regulatory approvals are in place, and commissioning is expected in FY27. The company is also engaging with potential pyrolysis oil customers.

Sustainability is positioned as both an operating priority and a stakeholder signal. The company received an EcoVadis Platinum rating in June 2026, placing it in the top 1 percent of global chemical companies. It achieved a 2025 CSA score of 78 in the DJSI framework, up from 62, placing it in the top 2 percent among more than 500 global chemical companies, and it is featured in the S and P Global Sustainability Yearbook 2026. Renewable energy contributed over 21 percent to total power purchased, with an expectation to reach 70 percent by the end of FY27. Over 95 percent of hazardous waste was recovered, recycled, and co-processed.

These points connect back to cost and execution. Higher renewable share can soften energy cost volatility over time, while better waste recovery can reduce compliance and disposal costs. They also matter for global customers who increasingly bake sustainability scoring into vendor qualification.

The near-term earnings levers: cost, ramp-ups, and capex

The company lays out a structured view of EBITDA growth drivers for FY26 to FY28. It splits the opportunity into three buckets.

Cost optimization is estimated at 150 to 200 crore, driven by initiatives including switching to a back pressure turbine to improve co-generation, renewable power phase 2, waste energy stream utilization, effluent treatment plant cost optimization, fixed cost optimization, yield improvement, and digital and advanced analytics led cost excellence initiatives.

Volume and margin ramp-up is estimated at 350 to 550 crore. The focus areas include acid, DCB and NCB value chain ramp-up, ethylation and NT volume ramp-up with downstream integration for select ethylation products, MMA capacity and volume ramp-up, and fluorination and specialty chemicals ramp-up.

Capex-led growth is estimated at 300 to 450 crore. This includes a pilot commissioned to fuel new product development, MPP commissioning and ramp-up, Zone 4 commissioning and ramp-up, and the commissioning and ramp-up of the Augene and Re Aarti joint ventures. The presentation indicates that all projects are expected to commission in FY27.

This framing is useful because it makes clear that the next phase is not dependent on one lever. Cost programs are already underway, ramp-ups depend on demand and internal execution, and capex-led growth relies on commissioning timelines. Investors will likely track FY27 updates on project completion, ramp curves, and how quickly utilization translates into margin improvement.

The long-term growth focus areas expand the narrative beyond the next few quarters. The company emphasizes MPP and Zone 4 commercialization, stating that R and D and MPP will support quick development, qualification, and commercialization of new advanced chemistries. It also points to chlorotoluene commissioning and ramp-up as opening new opportunities in agro and pharma.

Beyond the core, management highlights entry into adjacent markets and new platforms, including advanced materials, battery materials, defense, and coatings segments, and the development of growth platforms linked to sustainability and circularity. Strategic alliances and CDMO are another stated direction, with the company aiming to promote India as a manufacturing destination and leverage its R and D strength to provide CDMO services.

What investors should take away heading into FY27

FY26 tells a story of recovery that is real but not clean. Gross income rose to 9018 crore and EBITDA improved to 1172 crore, supported by strong volume growth and better utilization in key chains like NCB, DCB, NT, ethylation, and especially MMA and fuel additives. But the company is still working through margin pressure from a competitive landscape, tariff-linked disruptions in some products, and raw material volatility that raised working capital and debt.

The most important positive signal is the shape of the FY27 setup. The company has a 15-year contract amendment tied to backward integration, a 150 million US dollar supply contract running till March 2030 that should lift utilization without major capex, and multiple projects expected to commission in FY27, including Zone IV and joint ventures. It is also pushing measurable cost improvement programs and increasing renewable energy share, which could help protect margins over time.

The near-term test is execution. If FY27 commissioning and ramp-ups land on schedule, and if the volume recovery continues across energy, polymers, and parts of agro and pharma, Aarti Industries has a credible path to convert utilization gains into stronger profitability. And if raw material volatility stabilizes, working capital and leverage should become easier to manage. For investors, the core question is not whether demand has returned in pockets, it has. The question is how efficiently that demand can be converted into EBITDA while the company scales new projects and de-risks supply chains through long-term contracts.